Pfizer CEO Ian Read said he believes the Trump administration plans to stop the practice of allowing rebates on prescription drug purchases, indicating that U.S. drug pricing reforms may focus on middlemen instead of drug makers, Reuters reports. “I believe the administration does want to remove rebates, and they consider it a priority,” Read said in an interview
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.